Skip to main content
. 2023 Dec 27;16(1):140. doi: 10.3390/cancers16010140

Figure 1.

Figure 1

Study design of patients with RET fusion-positive aNSCLC or RET fusion-positive TC. Abbreviations: MKI, multikinase inhibitor; PD1/PD-L1, programmed death-1/programmed death ligand-1.